American CryoStem Completes Cell Processing for Clinical Study
February 07 2012 - 9:00AM
Marketwired
American CryoStem Corporation (OTCQB: CRYO) announced today that it
has completed providing stem cell processing services for Personal
Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin
care products.
The study involves researching the regenerative function of a
conditioned medium obtained from each participant's adipose (fat
tissue) derived mesenchymal stem cells and their ability to promote
the production or secretion of collagen, elastin and fibronectin
related to skin wound healing.
John Arnone, CEO of American CryoStem and Founder of Personal
Cell Sciences, commented, "CRYO's patented tissue culture media and
its proprietary, aseptic adipose tissue processing methodology
allows, as an added benefit for PCS customers to store a clinical
grade sample of their own stem cells for future use in regenerative
medicine. We are pleased to provide comprehensive Bio-Insurance
storage solutions at our clinical facility."
The adipose tissue samples were acquired utilizing a
mini-liposuction procedure. A total of sixty milliliters
(approximately 2 fluid ounces) of adipose tissue was collected in
the physician's office and sent to CRYO's laboratory for
processing. Once processed, the resulting stromal vascular fraction
(SVF) was forwarded to the Personal Cell Sciences laboratory for
proprietary formulation for patient specific products.
"We are very excited to announce our service agreement and
participation in this clinical study for Personal Cell Sciences.
This contractual manufacturing agreement reinforces our
capabilities to provide CRYO's exceptional clinical processing for
relevant adult stem cell related products," said Anthony Dudzinski,
COO of American CryoStem. "We look forward to our continued
business relationship with PCS and expanding these services to
other developers to speed their product's time to market."
About American CryoStem: American CryoStem
Corporation (OTCQB: CRYO) markets clinical processing products and
services for Adipose (fat) Tissue and Adipose Derived Adult Stem
Cells. CRYO's clinical processing and preservation platform
supports the science and applications being discovered globally by
providing the highest quality, clinically processed cells and
assuring their sterility, viability and growth cap abilities, while
at the same time developing cutting edge application, therapies and
laboratory products and services for consumers and physicians.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain of the
statements contained herein, which are not historical facts, are
forward-looking statements with respect to events, the occurrence
of which involve risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the Company is detailed from time to time in the
Company's reports filed with the Securities and Exchange
Commission.
Add to Digg Bookmark with del.icio.us Add to Newsvine
For More Information, contact: Investor Relations American
CryoStem Corporation 188 East Bergen Place, Suite 204 Red Bank, NJ
07701 Phone: 732-747-1007 www.americancryostem.com
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2023 to Jul 2024